Suppr超能文献

[螺内酯在皮肤科治疗中的应用。适应证的标注与未标注情况]

[Spironolactone in dermatological treatment. On and off label indications].

作者信息

Salavastru C M, Fritz K, Tiplica G S

机构信息

2nd Clinic of Dermatology, "Colentina" Clinical Hospital, Bucharest, Romania,

出版信息

Hautarzt. 2013 Oct;64(10):762-7. doi: 10.1007/s00105-013-2597-y.

Abstract

There are no currently FDA/EMEA-approved dermatologic indications for spironolactone and its off-label uses are, among others, female acne, female pattern hair loss, hidradenitis suppurativa or hirsutism. The rationale behind these relays on the mechanism of action of spironolactone which interferes with the hormone-controlled sebum and sweat gland secretion and with androgen stimulated hair growth. The average dose used by the dermatologits is 50-100 mg daily. It should not be used in pregnant and lactating women and it is not used in men due to the risk of feminization. Although further studies to assess its efficacy and safety are necessary, currently spironolactone is regarded as a useful tool in the dermatologic treatment armamentarium.

摘要

目前,螺内酯尚无美国食品药品监督管理局(FDA)/欧洲药品管理局(EMEA)批准的皮肤科适应症,其超说明书用途包括女性痤疮、女性型脱发、化脓性汗腺炎或多毛症等。这些用途背后的理论依据在于螺内酯的作用机制,它可干扰激素控制的皮脂和汗腺分泌以及雄激素刺激的毛发生长。皮肤科医生使用的平均剂量为每日50 - 100毫克。孕妇和哺乳期妇女不应使用,由于存在女性化风险,男性也不使用。尽管有必要进一步研究以评估其疗效和安全性,但目前螺内酯被视为皮肤科治疗手段中的一种有用工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验